LAGUNA HILLS, CA, November 07, 2020 – Arthrosi Therapeutics, a clinical-stage biopharmaceutical company focused on developing a best-in-class treatment for gout, has completed a Phase 2a clinical trial for company’s lead asset, AR882.
SUNNYVALE, Calif., Dec. 3, 2018 /PRNewswire/ -- NeuCyte, Inc., a leading neuroscience drug discovery company, announced that it has entered a license agreement with Boston Children's Hospital. As part of the agreement, Boston Children's has obtained a non-exclusive license from NeuCyte to manufacture transcription factor Ngn2 programmed induced neurons. The hospital intends to use this technology for internal research, teaching and educational purposes, and to perform services to other academic institutions.
UATP is proud to be partnering with leading payment technology company CITCON to offer Alipay, WeChat Pay and China UnionPay, the preferred mobile payment options for over one billion Chinese consumers.